Hetero is known for its expertise of developing APIs for more than 20 years. Today, it is the leading global supplier of APIs (including cytotoxics) to the pharmaceutical companies that manufacture formulations and new-generation products. Hetero enables customers to launch many first-time generics through its APIs. The company has concentrated on specific market needs where innovation in novel chemistry and low-cost manufacturing will substantially increase access to more patients across the world.
Hetero's APIs are currently manufactured in more than 18 facilities approved by the highest regulating bodies in each region. Since 1993, the company has produced more than 300 APIs with over 60 of them receiving market approvals in the US and Europe. Additionally, Hetero produces bulk APIs for regulated and semi-regulated markets